KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.85

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Mikkael A Sekeres, Amer M Zeidan, Valeria Santini, Rami S Komrokji, Pierre Fenaux, Michael R Savona, Yazan F Madanat, David Valcárcel, Antoine Regnault, Kristin Creel, Libo Sun, Ying Wan, Shyamala Navada, Tymara Berry, Faye Feller, Uwe Platzbecker, María Díez-Campelo, Esther Natalie Oliva

Haematologica 111(7) 2385-2396

PMID41568521
PMCIDPMC13317827
DOI10.3324/haematol.2025.288956
发表日期2026-01-22
入排依据:The report is from a randomized Phase III oncology trial with a drug intervention, but it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The main outcomes are patient-reported outcomes and quality of life, which are secondary/exploratory analyses.
摘要

摘要

Red blood cell (RBC) transfusions for anemia associated with lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) often contribute to reduced quality of life (QOL). Thus, reduction in RBC transfusion dependency (TD) is a primary therapeutic goal. Imetelstat is a first-in-class, competitive telomerase inhibitor approved to treat certain adult patients with LRMDS with RBC-TD anemia who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. In the phase III IMerge study (clinicaltrials.gov identifier: NCT02598661), treatment with imetelstat resulted in clinically meaningful, statistically significant increases in the primary endpoint of ≥8-week RBC transfusion independence (TI) versus placebo. Because patients with LR-MDS experience detrimental effects on numerous facets of QOL (physical, emotional, social, and functional), these exploratory analyses assessed patient-reported outcomes using the Functional Assessment of Chronic Illness Therapy-Fatigue, Quality of Life in Myelodysplasia Scale, and Functional Assessment of Cancer Therapy-Anemia questionnaires as part of the phase III IMerge study. Nominal P values were reported. Fewer imetelstat-treated patients experienced deterioration in fatigue levels and more imetelstat-treated patients experienced sustained improvement in fatigue levels and QOL versus placebo. In the imetelstat group, 8-week, 24-week, and 1-year RBC-TI responders had sustained improvements in predefined significance thresholds versus non-responders for fatigue (70%, 73%, and 88%, respectively, vs. 37%, 41%, and 44%, respectively; P<0.001, P=0.004, and P=0.002) and QOL across different measures of response (43-53% vs. 21-30%; P≤0.0126). These results suggest that treatment with imetelstat may be associated with improvement in QOL beyond fatigue while sustaining RBC-TI in patients with LR-MDS with RBC-TD anemia.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 4.

Time to first sustained improvement a in QUALMS scores (patient-reported outcomes population). QUALMS Total (A), QUALMS-P (B), and QUALMS-E (C). Sustained meaningful improvement was defined for QUALMS as ≥9-, ≥8-, or ≥9-point increase for ≥2 consecutive assessments in QUALMS Total, QUALMS-P, and QUALMS-E scores, respectively. 35 NE: not estimable; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale - emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale - physical burden.

A

Time to first sustained improvement in QUALMS Total

Figure 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start
查看结果
B

Time to first sustained improvement in QUALMS-P

Figure 4. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start
查看结果
C

Time to first sustained improvement in QUALMS-E

Figure 4. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span曲线 2:off origin start
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Sustained meaningful improvement a in FACIT-Fatigue, QUALMS Total, QUALMS-P, and QUALMS-E scores (patient-reported outcomes population). a Defined for fatigue as a ≥3-point increase in FACIT-Fatigue score for ≥2 consecutive assessments, for QUALMS as ≥9-, ≥8-, or ≥9-point increase for ≥2 consecutive assessments in QUALMS Total, QUALMS-P, and QUALMS-E scores, respectively. 35 FACIT: Functional Assessment of Chronic Illness Therapy; n/N: number with event/number in population; PRO: patient-reported outcome; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale - emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale - physical burden.
非 KM Figure
Figure 2.Sustained meaningful improvement a in different quality of life measures by subgroup (patient-reported outcomes population). FACIT-Fatigue (A) and QUALMS Total, QUALMS-P, and QUALMS-E (B) scores. a Defined for fatigue as a ≥3-point increase in FACIT-Fatigue score for ≥2 consecutive assessments, for QUALMS as ≥9-, ≥8-, or ≥9-point increase for ≥2 consecutive assessments in QUALMS Total, QUALMS-P, and QUALMS-E scores, respectively. 35 EPO: erythropoietin; FACIT: Functional Assessment of Chronic Illness Therapy; IPSS: International Prognostic Scoring System; HTB: high transfusion burden; IWG: International Working Group; LTB: low transfusion burden; n/N: number with event/number in population; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale - emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale - physical burden; RS: ring sideroblast.
非 KM Figure
Figure 3.Change from baseline in different measures of quality of life by cycle (ITT population). FACIT-Fatigue (A), QUALMS Total, QUALMS-P, and QUALMS-E (B), and FACT-An (C) scores. C: cycle; D: day; FACIT: Functional Assessment of Chronic Illness Therapy; FACT-An: Functional Assessment of Cancer Therapy-Anemia; ITT: intention-to-treat; N: number; PRO: patient-reported outcome; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale – emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale – physical burden; SE: standard error.
非 KM Figure
Figure 5.Improvements a in quality of life measures by response to imetelstat (patient-reported outcomes population). FACIT-Fatigue b (A) and QUALMS Total, c QUALMS-P, c and QUALMS-E c scores (B). Sustained meaningful improvement was defined for fatigue as a ≥3-point increase in FACIT-Fatigue score for ≥2 consecutive assessments, for QUALMS as ≥9-, ≥8-, or ≥9-point increase for ≥2 consecutive assessments in QUALMS Total, QUALMS-P, and QUALMS-E scores, respectively. 35 b P values by Fisher exact test. c P values by X 2 test. FACIT: Functional Assessment of Chronic Illness Therapy; Hb: hemoglobin; HI-E: hematologic improvement-erythroid; n/N: number with event/number in population; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale - emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale - physical burden; RBC: red blood cell; TI: transfusion independence.
非 KM Figure